(Q43682877)

25 November 2017

title

Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery (English)

1 reference

25 November 2017

1 reference

R J Riley

1

1 reference

25 November 2017

A J Parker

series ordinal

2

1 reference

25 November 2017

S Trigg

series ordinal

3

1 reference

25 November 2017

C N Manners

series ordinal

4

1 reference

25 November 2017

publication date

1 May 2001

1 reference

25 November 2017

published in

Pharmaceutical Research

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

652-655

1 reference

Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

25 November 2017

cites work

1 reference

12 December 2020

Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli

1 reference

12 December 2020

In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin

1 reference

12 December 2020

Human cytochrome P450s: selectivity and measurement in vivo

1 reference

12 December 2020

Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

1 reference

12 December 2020

Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors

1 reference

12 December 2020

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

12 December 2020

Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

Drug-drug interactions of new active substances: mibefradil example

1 reference

12 December 2020

Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450

1 reference

12 December 2020

Understanding consequences of concurrent therapies

1 reference

12 December 2020

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

1 reference

12 December 2020

Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

12 December 2020

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011085411050

1 reference

25 November 2017

1 reference